# A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

> **NCT05703516** · — · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 250 (estimated)

## Conditions studied

- Non-Small-Cell Lung Carcinoma

## Interventions

- **OTHER:** Capmatinib

## Key facts

- **NCT ID:** NCT05703516
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-12
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2025-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05703516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05703516, "A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05703516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*